CANCRO FEGATO NON OPERABILE. NIVOLUMAB PIU’ IPILIMUMAB > LENVATINIB OR SORAFENIB IN PRIMA LINEA. UN TRIAL RANDOMIZZATO DA “THE LANCET” (FREE!)

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial Thomas Yau et al. Summary Background Patients with unresectable hepatocellular carcinoma have a poor prognosis, and treatments with long-term benefits are needed. We report results from the preplanned interim analysis of the CheckMate 9DW…

PANCREATITE ACUTA SEVERA: ESISTE UN RUOLO PER I COXIB! ATTENZIONE! RIDUCONO LA DURATA DELLA PANCREATITE E LE COMPLICAZIONI. UN TRIAL SU 348 PAZIENTI DA “GUT” (FREE!)

Parecoxib sequential with imrecoxib for occurrence and remission of severe acute pancreatitis: a multicentre, double-blind, randomised, placebo-controlled trial  Luming Huang et al. Abstract Background There is no effective drug treatment for the organ failure (OF) caused by severe acute pancreatitis (SAP). Objective We aimed to evaluate the efficacy of cyclooxygenase-2 inhibitors (COX-2-Is) on the treatment of SAP…

SORVEGLIANZA HCC NEL CIRROTICO: E’ MEGLIO LA RMN SENZA CONTRASTO RISPETTO ALL’ECOGRAFIA ! UN OTTIMO TRIAL DA “GASTROENTEROLOGY” (OCCHIO AI FALSI POSITIVI DELLA ECOGRAFIA!)

Noncontrast Magnetic Resonance Imaging vs Ultrasonography for Hepatocellular Carcinoma Surveillance: A Randomized, Single-Center Trial Hyungjin Rhee et al. Abstract Background & Aims This study aimed to compare ultrasonography (US) and noncontrast magnetic resonance imaging (MRI) in the surveillance of hepatic malignancy. Methods We conducted a randomized, nonblinded trial at a single center in South Korea. Eligible…

LE NUOVE SCOPERTE NELLA SCIENZA STANNO RALLENTANDO! UNA RIFLESSIONE DA “NATURE” (FREE!)

Are groundbreaking science discoveries becoming harder to find? Researchers are arguing over whether ‘disruptive’ or ‘novel’ science is waning – and how to remedy the problem. David MatthewsRussell Funk had no idea how much his work would strike a nerve. But then came a blizzard of news stories and supportive e-mails from hundreds of scientists…

RECALL: GLI ANTIDEPRESSIVI SSRI PROVOCANO EMORRAGIA DIGESTIVA: + 36% (12% a 64%). DA “Pharmacological Research” (FREE!)

Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: A meta-analysis of observational studies  Silvy Laportea et al. Selective serotonin reuptake inhibitors (SSRIs) have been reported to be potentially associated with an increased risk of bleeding. A meta-analysis of observational studies was conducted to quantify this risk. Case-control and cohort studies investigating bleeding risk under…